

1 **Cardiovascular vulnerability predicts hospitalisation in primary care clinically**  
2 **suspected and confirmed COVID-19 patients: a model development and validation study**

3  
4 Florien S. van Royen<sup>1\*</sup>, Linda P.T. Joosten<sup>1</sup>, Maarten van Smeden<sup>2</sup>, Frans H. Rutten<sup>1</sup>, Geert-  
5 Jan Geersing<sup>1</sup>, Sander van Doorn<sup>1</sup>

6  
7 <sup>1</sup> Dept. General Practice, Julius Center for Health Sciences and Primary Care, University  
8 Medical Center Utrecht, Utrecht University, Utrecht, Netherlands

9 <sup>2</sup>Dept. Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical  
10 Center Utrecht, Utrecht University, Utrecht, Netherlands

11 \*Corresponding author, e-mail: [f.s.vanroyen-5@umcutrecht.nl](mailto:f.s.vanroyen-5@umcutrecht.nl)

12  
13 **Abstract**

14 *Introduction*

15 Cardiovascular disease and diabetes have shown to be predictive of clinical deterioration  
16 towards critical illness or death in the hospitalised COVID-19 patient population. The aim of  
17 this study was to determine the incremental value of cardiovascular vulnerability - defined by  
18 the number of cardiovascular diseases and/or diabetes - in predicting the risk of escalation of  
19 care towards hospital referral in primary care patients with clinically suspected or confirmed  
20 COVID-19.

21  
22 *Methods*

23 Data were retrospectively collected from three large Dutch primary care registries with routine  
24 care data of ±850,000 people. A prognostic prediction model was developed in two databases  
25 to assess the incremental value of cardiovascular vulnerability. Data from the ‘first wave’ of  
26 COVID-19 infections in the Netherlands (March 1 2020 to June 1 2020) was used for  
27 derivation. A multivariable logistic regression model was fitted to predict hospital referral within

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 90 days follow-up after first consultation in consecutive adult patients seen in primary care for  
29 COVID-19 symptoms. Age, sex, the interaction between age and sex, and the number of  
30 underlying cardiovascular diseases and/or diabetes (0, 1, or  $\geq 2$ ) were pre-specified as  
31 predictors prior to the analyses. The model was (i) compared to a simpler model without the  
32 predictor number of cardiovascular diseases and/or diabetes and (ii) externally validated in  
33 COVID-19 confirmed patients during the 'second wave' (June 1 2020 to April 15 2021) in all  
34 three databases.

35

### 36 *Results*

37 There were 5,475 patients included for model development and 6.8% had the primary outcome  
38 hospital referral. The model with number of cardiovascular diseases included as a predictor  
39 performed better than a model without this predictor (likelihood ratio test  $p < 0.001$ ). Older male  
40 patients with multiple cardiovascular diseases and/or diabetes had the highest predicted risk  
41 of hospital referral, reaching risks above 15-20% in these patients. The model was externally  
42 validated in a population of 16,693 COVID-19 patients. The observed risk was lower in this  
43 temporal validation cohort (4.7% versus 6.8%). The temporally validated c-statistic was 0.747  
44 (95%CI 0.729-0.764) and the model showed good calibration.

45

### 46 *Conclusion*

47 In this general population study, risk of clinical deterioration after suspected or confirmed  
48 COVID-19 was on average 5.1% in the development and validation cohorts combined. This  
49 risk increased with age and was higher in males compared to females. Importantly, patients  
50 with concurrent cardiovascular disease and/or diabetes had higher predicted risks. Identifying  
51 those at risk for hospital referral could have clinical implications for COVID-19 early disease  
52 management in primary care.

53

54

55

## 56 **Introduction**

57 Coronavirus disease 2019 (COVID-19) has led to a global pandemic ever since the first cases  
58 were described in late 2019. In order to orchestrate the flow of patients depending on the  
59 expected course of the disease, the need arose for risk profiling patients suffering most from  
60 COVID-19. Since then, a fast-growing amount of prediction models have been developed for  
61 prognosticating COVID-19 patients. However, most of these models focus on an in-hospital  
62 population, with only few prediction models focusing on the community.(1) This is unfortunate  
63 as the clinical presentation of (suspected) COVID-19 starts-off with initially mild to moderate  
64 symptoms in the first week of illness, and only in some with progression to hypoxemia for which  
65 hospital (or even ICU) admission is needed, typically occurring in the second week of illness.(2)  
66 If such deterioration occurs, the primary care physician is often the first to decide on the need  
67 and optimal timing for more impactful measures, such as intensified monitoring or ultimately  
68 hospitalisation. In hospitalised COVID-19 patients, underlying cardiovascular diseases have  
69 been identified as strong predictors for further disease deterioration towards ICU admittance  
70 or death.(3–7) The incremental value of cardiovascular diseases and/or diabetes in predicting  
71 escalation of care in primary care COVID-19 patients has, however, yet to be determined.

72

73 The aim of this study was to determine the incremental value of cardiovascular vulnerability –  
74 defined by the number of cardiovascular disease and/or diabetes – in predicting the risk of  
75 hospital referral in primary care patients with clinically suspected or confirmed COVID-19.  
76 Results from this analysis are intended to value concurrent cardiovascular disease in  
77 community COVID-19 patients, and to support clinical decision making on COVID-19 early  
78 disease management for primary care physicians.

79

## 80 **Methods**

### 81 *Study design*

82 This study involves an analysis of observational data of community people registered by the  
83 primary care physician with confirmed and clinically suspected COVID-19 patients. We

84 assessed the incremental value of cardiovascular disease and/or diabetes by developing a  
85 prognostic prediction model in a cohort of patients from the ‘first wave’ of COVID-19 infections  
86 in the Netherlands (March 1 2020 to June 1 2020) that was temporally validated in a cohort of  
87 patients from the ‘second wave’ of infections in the Netherlands (June 1 2020 to April 15 2021).  
88 Where appropriate for this study, we adhered to the TRIPOD guideline for reporting prediction  
89 models.(8)

90

### 91 *Databases*

92 Patients were included from three similar ongoing and dynamic Dutch primary care registries  
93 containing pseudo-anonymous medical data of approximately 850,000 patients: the Julius  
94 General Practitioner’s Network (JGPN) Utrecht, the ‘Academisch Netwerk  
95 Huisartsgeneeskunde VU’ (ANH) Amsterdam, and the ‘Academisch Huisartsennetwerk AMC’  
96 (AHA) Amsterdam.(9–11) Two databases (JGPN and ANH) were used to identify patients for  
97 the development of the prediction model (i.e. development cohort) and all three databases  
98 (JGPN, ANH and AHA) were used to identify patients for the temporal validation (i.e. the  
99 validation cohort).

100

### 101 *Study population and data collection*

102 Patients for the development cohort were included from March 1 2020 to June 1 2020 (the ‘first  
103 wave’ of the COVID-19 pandemic in the Netherlands). During this time period, very limited  
104 polymerase chain reaction (PCR) testing for COVID-19 was available and mainly restricted to  
105 more severe hospitalised cases. Consequently, many patients with symptoms that were highly  
106 suggestive of COVID-19 were not being tested. To create a representative patient sample we  
107 therefore included all consecutive adult patients aged 18 years or older, who visited their  
108 primary care physician with confirmed COVID-19 as well as those with symptoms that were  
109 clinically suspected.

110

111 For identification of the study population and data collection, the same methods were applied  
112 in all three databases. Dutch primary care physicians link diagnoses and clinical symptoms to  
113 the electronic medical records as diagnostic codes using the International Classification of  
114 Primary Care (ICPC) coding system. The primary care physicians supplying clinical data to the  
115 JGPN, AHA and ANH databases are trained in and experienced with using ICPC codes. For  
116 the development cohort, COVID-19 suspected patients were identified using the ICPC codes  
117 R74 (acute upper respiratory infection), R81 (pneumonia) and R83 (other respiratory infection).  
118 At the time of reporting, primary care physicians were recommended to use R81 and R83 for  
119 indicating COVID-19 suspected and COVID-19 confirmed cases respectively. Records of  
120 patients labelled with ICPC R74 (unspecified acute upper respiratory infection) were manually  
121 screened for COVID-19 suspicion in the consultation text by three clinical scientists (FSvR,  
122 LPTJ, and SvD) and cases of doubt were discussed until agreement was reached. Patients  
123 with ICPC R74 and not having a synonym of or reference to COVID-19 suspicion or related  
124 symptoms in this text were excluded. Of all included patients, baseline characteristics (i.e. age;  
125 sex; comorbidities; and where available Body Mass Index (BMI), oxygen saturation and C-  
126 Reactive Protein (CRP)) were collected. Comorbidities (i.e. cardiovascular disease, pulmonary  
127 disease, cancer), and history of relevant diseases were identified using ICPC. Supplementary  
128 table 1 contains all ICPC codes that were used for this study.

129  
130 For the validation cohort, consecutive adult JGPN patients were included from September 1  
131 2020 until April 15 2021, and consecutive adult AHA and ANH patients were included from  
132 June 1 2020 until December 31 2020 (the 'second wave' of COVID-19 infections). At this point  
133 in time, PCR COVID-19 tests were available for all symptomatic patients in the Netherlands,  
134 and confirmed cases were routinely coded by primary care physicians using ICPC coding in  
135 medical records (R83 and R83.03). Thus, only confirmed COVID-19 cases (i.e. with ICPC R83  
136 and R83.03) were included during the 'second wave' of the COVID-19 pandemic in the  
137 Netherlands for validation of the model.

138

139 *Outcome*

140 The primary outcome of this study and the outcome of the prediction model was referral to an  
141 emergency ward for intended hospital admission. This was defined as any escalation of care  
142 resulting in hospital referral by the primary care physician and as such recorded in the  
143 consultation text of the medical record. To capture the full spectrum of complications of COVID-  
144 19 resulting in hospitalisation, follow-up lasted 90 days after first consultation for COVID-19  
145 suspected symptoms. For this, consultation texts were manually screened for any emergency  
146 hospital referral and its synonyms by (primary care) clinical scientists (FSvR, LPTJ, SvD, and  
147 GJG) and cases of doubt were discussed, again until consensus was reached.

148

149 *Candidate predictors*

150 Based upon existing literature from hospitalised COVID-19 patients, we a-priori specified the  
151 following candidate predictors prior to the analysis phase: age, sex, the interaction between  
152 age and sex, and the number of cardiovascular diseases. Cardiovascular diseases were  
153 defined as (history of) type 2 diabetes mellitus, heart failure, coronary artery disease,  
154 peripheral arterial disease, stroke/transient ischemic attack (TIA), venous thromboembolism  
155 (pulmonary embolism or deep venous thrombosis; VTE), and/or atrial fibrillation (AF). These  
156 cardiovascular diseases were deemed present if the primary care physician had used  
157 corresponding ICPCs (supplementary table 1) at any point before the index date in the patient's  
158 medical record. In absence of an ICPC code the disease was assumed to be absent. The  
159 number of cardiovascular diseases were counted per patient and categorised in one of three  
160 categories: no cardiovascular disease, one cardiovascular disease, or two or more  
161 cardiovascular diseases.

162

163 *Sample size*

164 The model development cohort in JGPN and ANH yielded 5,475 eligible patients with an event  
165 fraction of 0.068 (6.8%, n=373) for the primary outcome referral to the hospital. Prior to  
166 prediction analysis, the number of allowed candidate predictors was determined. Based on the

167 proposed calculation for sample size in prediction modelling by Riley et al.(12), the maximum  
168 number of candidate predictors that can be modelled was 30 with a  $R^2$  Cox-Snell ( $R^2_{cs}$ ) of  
169 0.0495. As this  $R^2_{cs}$  was estimated in absence of a known value, varying  $R^2_{cs}$  from 0.0395 to  
170 0.0595 yielded a minimum of 24 and a maximum of 37 candidate predictors, including  
171 interaction terms. By using the candidate predictors age, sex, the interaction between age and  
172 sex, and the number of cardiovascular diseases with three categories, the amount is  
173 considerably lower than the maximum of allowed candidate predictors, and therefore the  
174 sample size of 5,475 eligible patients was deemed sufficient and large enough for model  
175 development.

176

#### 177 *Missing data*

178 Candidate predictors age, sex and cardiovascular disease had no missing data. Missing values  
179 in baseline of characteristics measurements of CRP, BMI and oxygen saturation level were  
180 not imputed as these determinants were not used further in predictive modelling.

181

#### 182 *Statistical analyses*

183 Baseline characteristics were summarised using descriptive statistics with categorical  
184 variables as numbers with percentages and continuous variables as means with standard  
185 deviations or medians with interquartile ranges (IQR). A multivariable logistic regression  
186 modelling approach was used. All included patients were entered in a fixed model (full model)  
187 with the predictors age, sex, the interaction between age and sex, and the number of  
188 cardiovascular diseases with three categories. To determine the incremental value of the  
189 predictor number of cardiovascular diseases, a second model (simple model) was fitted using  
190 only the predictors age, sex, and the interaction between age and sex. Age was considered as  
191 a continuous variable and was studied using a restricted cubic spline function to account for  
192 possible non-linearity with 4 knots on the percentiles 0.05, 0.35, 0.65 and 0.95.(13) Number of  
193 cardiovascular diseases was taken as a dummy variable with 'no cardiovascular disease' as  
194 reference category. The incremental value of number of cardiovascular diseases was studied

195 comparing the two models c-statistics ( $\Delta$ AUC), Cox-Snell  $R^2$ cs ( $\Delta R^2$ cs), and a likelihood ratio  
196 test. To determine incremental value, an alpha of 0.05 was used for the likelihood ratio test.  
197 The full model was internally validated using Harrell's bootstrapping with 100 repetitions to  
198 obtain optimism corrected estimates of the c-statistic and  $R^2$ , and slope were calculated. For  
199 temporal external validation of the full model, calibration and discrimination were evaluated:  
200 observed and predicted events are shown in calibration plots and for discrimination areas  
201 under the curve (AUC/c-statistic) are given. Other performance measures for temporal external  
202 validation that are reported are: calibration slope, calibration intercept, calibration in the large,  
203  $R^2$ cs, and Brier score. Brier score assesses the overall goodness of fit of the model with smaller  
204 numbers indicating better performance. Confidence intervals for c-statistics were obtained  
205 using the Delong method. For  $R^2$ cs and Brier score confidence intervals, bootstrapping was  
206 used with repetitions set at 1000. Validation was done in the whole validation dataset as well  
207 as separately in the JGPN, ANH, and AHA validation datasets. All statistical analyses were  
208 performed in R version 4.0.3 with R base, rms, pROC, DescTools, and rmda packages.(14–  
209 18)

210

### 211 *Ethics*

212 This research was conducted in accordance with Dutch law and the European Union General  
213 Data Protection Regulation and according to the principles of the Declaration of Helsinki. The  
214 need for formal ethical reviewing was waived by the local medical research ethics committee  
215 of the University Medical Center Utrecht, the Netherlands as the research did not require direct  
216 patient or physician involvement.

217

## 218 **Results**

### 219 *Patient characteristics*

220 Patient characteristics of the development cohort are described in table 1. There were 5,475  
221 patients included in this cohort: 2,825 from JGPN and 2,650 from ANH. In JGPN, the median



222 age was 48 (IQR 34-62) years and 40.1% were male. 64.6% of the patients were coded as  
223 R74, 14.7% as R81, and 21.3% as R83. In ANH, the median age was 49 (IQR 36-62) years  
224 and 40.3% were male. 71.5% were coded as R74, 10.7% as R81, and 19.2% as R83.  
225 Differences between both datasets in the development cohort were minor. Around a quarter of  
226 patients suffered from one or more cardiovascular disease, most often type 2 diabetes and  
227 coronary artery disease.

228  
229 Patient characteristics of the COVID-19 confirmed patients in the validation cohort are  
230 described in table 2. The total of 16,693 patients for validation could be divided in 5,420 from  
231 JGPN, 4,989 from ANH, and 6,284 from AHA. In JGPN, the median age was 43 (IQR 30-56)  
232 years and 44.3% were male. In ANH, the median age was 47 (IQR 34-59) years and 42.5%  
233 were male and in the AHA dataset, the median age was 49 (IQR 36-60) years and 39.2% were  
234 male. The differences between these three datasets in the validation cohort were also minor.  
235 Around 15-20% suffered from one or more cardiovascular disease, again most often type 2  
236 diabetes and coronary artery disease.

237  
238 *Model development and internal validation*

239 All 5,475 patients were used for model development. 373 patients (6.8%) had the outcome  
240 hospital referral. All predefined model regression coefficients of the two models (i.e. age, sex,  
241 interaction between age and sex, and the number of cardiovascular diseases with three  
242 categories), with confidence intervals are shown in table 3. The apparent c-statistic of the full  
243 model was 0.693 (95%CI 0.665-0.721) and the internally validated c-statistic was 0.688  
244 (95%CI 0.660-0.716). The apparent c-statistic of the simple model was 0.681 (95%CI 0.653-  
245 0.710) and the internally validated c-statistic was 0.680 (95%CI 0.652-0.708). The full and the  
246 simple model are compared in table 4. The full model performed significantly better than the  
247 simple model (p- value for likelihood ratio test,  $\chi^2 = 19.5$ ,  $df = 2$ ,  $p < 0.001$ ). Figure 1 gives a  
248 visual representation of the full prediction model showing the predicted risks for hospitalisation  
249 as a function of (increasing) age, stratified by sex and by the number of underlying

250 cardiovascular diseases and/or diabetes. Overall risks are higher for male patients and  
251 increase with age. Furthermore, a higher risk is observed in patients with underlying  
252 cardiovascular disease.

253

#### 254 *Temporal external validation*

255 Predicted risks were overall slightly higher than the observed risk (6.2% versus 4.6%) and the  
256 calibration slope was 1.36. Overall discrimination showed an AUC of 0.747 (95%CI 0.729-  
257 0.764). All combined and individual database validation performance measures are shown in  
258 table 5. Figure 2 shows the overall calibration plot and the calibration plots per database  
259 separately are given in the supplementary materials. The outcome prevalence was lower in  
260 the validation datasets than in the development datasets (4.7% versus 6.8%), probably  
261 explaining the overestimation in predicted risks by the model.

262

#### 263 **Discussion**

264 Cardiovascular vulnerability is a predictor of escalation of care in a population of 5,475  
265 consecutive adult patients in primary care with confirmed or clinically suspected COVID-19 in  
266 the 'first wave' of infections in the Netherlands. This finding was confirmed by external  
267 validation in a population of 16,693 confirmed COVID-19 primary care patients in the 'second  
268 wave', exemplifying the robustness of our inferences. On average, in 22,168 primary care  
269 patients 5.1% was referred to the hospital for considering admission. A model including the  
270 number of concurrent cardiovascular conditions and/or diabetes (0, 1, or  $\geq 2$ ) in addition to age  
271 and sex showed moderate to good performance and demonstrated consistent and good  
272 discrimination and calibration upon temporal external validation. The model showed a c-  
273 statistic of 0.747 (95%CI 0.729-0.764).

274

275 Although most COVID-19 patients experience a favourable prognosis without the need for  
276 referral for hospital care, studies on COVID-19 mainly focussed on those seen in the hospital

277 setting. While on average the risk for hospitalisation in adult community people with COVID-  
278 19 is low (5.1%), it is much higher than the hospitalisation rate for other lower respiratory  
279 infections which is estimated at approximately 1% of the adult population affected.(19) In our  
280 study, age, sex and the number of concurrent cardiovascular conditions and/or diabetes can  
281 identify specific patients at far greater risk of hospitalisation. In fact, for female patients without  
282 cardiovascular comorbidity, the risk of clinical deterioration for which hospital referral was  
283 deemed necessary remains well below 10% even in the eldest elderly (aged 80+), while in the  
284 presence of cardiovascular diseases and/or diabetes, patients experience higher risks already  
285 at younger ages, notably males. For instance, a male patient with two or more underlying  
286 cardiovascular diseases will reach a predicted risk of 15% already at the age of around 57  
287 years and this predicted risk will even further increase to above 20% from the age of 80  
288 onwards. This indicates the incremental effect of cardiovascular diseases and/or diabetes in  
289 addition to age and sex in predicting the risk for complicated COVID-19 disease trajectories in  
290 primary care patients.

291  
292 Our findings overall confirm those from previous studies done in the hospital setting where age  
293 and male sex are important predictors for disease progression towards the endpoints ICU  
294 admission or death.(1,20–22) Social, behavioural, comorbidity and biological differences  
295 (ACE2 expression, sex-hormones, X-chromosome exposure) between male and female sexes  
296 all might contribute to the higher risks of COVID-19 progression observed in males, although  
297 probably not all mechanisms have been fully elucidated yet.(23,24) Also, in *hospitalised*  
298 patients, it has been demonstrated that there is an association between cardiovascular disease  
299 and COVID-19 complicated disease trajectories, with higher prevalence of cardiovascular  
300 disease and diabetes described in those with critical illness. (3–7,25) Our study shows that this  
301 prognostically unfavourable effect is already present much earlier on in the COVID-19 disease  
302 course, at the start of symptoms in primary care.

303

304 This is in line with previous research, where this additive effect of (cardiovascular)  
305 comorbidities was also described by the 4C Mortality Score.(26) In this study, the authors  
306 demonstrated that the number of comorbidities, importantly including cardiovascular  
307 comorbidities, had a more predictive effect than taking only individual co-morbidities in  
308 predicting in-hospital mortality of COVID-19 patients.(26) Furthermore, there are two large  
309 community-based prediction studies also highlighting the importance of cardiovascular  
310 comorbidities as a predictor in the community COVID-19 population. The QCOVID model that  
311 was developed in the UK was based on data from primary care and showed excellent  
312 discrimination (c-statistic >0.9) for the primary outcome time to death from COVID-19. The  
313 domain of that study, however, covered the whole general population *regardless* of COVID-19  
314 diagnosis and therefore this can best be interpreted as the risk prediction of getting infected  
315 with COVID-19 *and* subsequently having complications from COVID-19. Thus, the aim of this  
316 model was to inform UK health policy and support interventions to manage COVID-19 related  
317 risks, rather than inform medical decision making during patient consultations in confirmed or  
318 clinically suspected COVID-19 cases.(27) With only 0.07% with the outcome death, and thus  
319 very low a priori chance, the c-statistic 'misleadingly' moves towards 1.0. Another similar public  
320 health based UK study in patients with and without COVID-19 identified determinants that were  
321 associated with COVID-19 related death in the OpenSAFELY primary care database by linking  
322 primary care records to reported COVID-19 related deaths. It found the most predictive clinical  
323 determinants to be increasing age, male sex, type 2 diabetes mellitus, and cardiovascular  
324 disease, similar to our findings.(28) While the domain notably differs between patients seeking  
325 care for COVID-19 symptoms in our study and the adult community as a whole in these studies  
326 from the UK, all draw similar conclusions on the increased risk of clinical deterioration in  
327 patients with cardiovascular disease.

328

### 329 *Strengths and limitations*

330 This research contributes to the evidence-based prognostication of community COVID-19. We  
331 were able to use a large and representative database capturing both the 'first' and 'second'

332 wave of the COVID-19 in the Netherlands. We used state-of-the-art methodology including  
333 external temporal validation to predict clinical deterioration in a patient population that currently  
334 is understudied. For full appreciation of our findings, however, some limitations also need to  
335 be addressed. First, the model was developed in a dataset with a low event fraction of the  
336 outcome hospital referral, yet the actual number of hospital referral events did allow us to  
337 perform robust multivariable regression techniques. Second, there are limitations to using  
338 routine care registry data that could have resulted in misclassification of the study population,  
339 predictors and outcome, and most importantly has the risk of missing values. For example,  
340 uncertainty concerning COVID-19 infection status may exist as COVID-19 PCR test results  
341 are not automatically linked to the primary care electronic medical records. However, the model  
342 proved its transportability in primary care patients in a different time period with satisfactory  
343 calibration and discrimination, during a time window where PCR testing was widely performed.  
344 Furthermore, the outcome hospital referral was based upon a rigorous manual extraction of  
345 medical records by pairs of researchers, yet not based upon actual linkage to hospital records.  
346 Additionally, there are differences between our development and validation population: the  
347 patients from the ‘first wave’ are all symptomatic patients that visited their primary care  
348 physician for symptoms suggestive of COVID-19, while the patients from the ‘second wave’ –  
349 due to government recommendation for individuals to get tested even in the circumstance of  
350 only mild symptoms – also include more healthy people that just informed their primary care  
351 physician of their positive COVID-19 PCR status. This could also explain the lower event  
352 fraction in the validation set (4.7% versus 6.8% in the development population). Finally, the  
353 incremental value of cardiovascular disease on prognosticating COVID-19 was assessed in  
354 different ways; although we did observe a highly significant change in the likelihood ratio test,  
355 the delta in c-statistic and  $R^2$ cs was only small to modest. Possible reasons for this include the  
356 overall low risk of hospitalisation in most patients in our cohort, as well as that most patients  
357 (80.2%) in fact in our cohort did not suffer from concurrent cardiovascular diseases and/or  
358 diabetes, and it has been widely acknowledged that, notably in such scenario’s, a change in  
359 e.g. the c-statistic is difficult to achieve.

360

### 361 *Clinical implications*

362 The simplicity of the chosen predictors and the clinical applicability may provide great  
363 advantages for risk profiling patient with suspected or confirmed COVID-19 in the primary care  
364 and community setting. This can have several important clinical implications. First, it may be  
365 possible to identify patients that will benefit from closer monitoring and frequent follow-up at  
366 home by predicting the risk of clinical deterioration early on in the COVID-19 disease course.  
367 By intensified monitoring of higher risk patients, critical illness may be detected earlier,  
368 potentially improving prognosis. Second, risk prediction could also support advanced care  
369 planning. Informing both patients and physicians on the risk of severe illness, may help in  
370 anticipating a more stringent or more lenient management. Last, risk profiling may be used for  
371 targeting treatment. Vaccination strategies to *prevent* COVID-19, for instance, may focus on  
372 those with cardiovascular disease and/or diabetes first. Additionally, experimental regimens  
373 to *treat* COVID-19 may be addressed to high-risk patients that may benefit most. Examples  
374 include for instance treatment with budesonide or colchicine; both treatment options likely  
375 benefit patients most at higher prior probability of having an adverse prognosis.(29,30)  
376 Nevertheless, in the end, risk prediction in primary care has to prove its value in daily practice  
377 at the background of changing characteristics of this challenging COVID-19 pandemic and  
378 influences of virus mutations. We however do hope that prognostic studies, like ours, may aid  
379 physician by making informed, evidence-based decisions and thereby improve patient  
380 outcomes.

381

### 382 **Conclusion**

383 In this general population study, risk of clinical deterioration after suspected or confirmed  
384 COVID-19 was on average 5.1%. This risk increased with age and was higher in males  
385 compared to females. Importantly, patients with concurrent cardiovascular disease and/or  
386 diabetes had higher predicted risks. Identifying those at risk for hospital referral could have  
387 clinical implications for COVID-19 early disease management in primary care.

388 **References**

- 389 1. Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E et al. Prediction  
390 models for diagnosis and prognosis of covid-19: systematic review and critical  
391 appraisal. *BMJ*. 2020;369: m1328.
- 392 2. Gandhi R, Lynch J, del Rio C. Mild or Moderate Covid-19. *New England Journal of*  
393 *Medicine*. 2020;383(18):1757-1766.
- 394 3. Linschoten M, Peters S, van Smeden M, Jewbali L, Schaap J, Siebelink H et al.  
395 Cardiac complications in patients hospitalised with COVID-19. *European Heart Journal*  
396 *Acute Cardiovascular Care*. 2020;9(8):817-823.
- 397 4. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L et al. Prevalence and impact of  
398 cardiovascular metabolic diseases on COVID-19 in China. *Clinical Research in*  
399 *Cardiology*. 2020;109(5):531-538.
- 400 5. Bello-Chavolla O, Bahena-López J, Antonio-Villa N, Vargas-Vázquez A, González-  
401 Díaz A, Márquez-Salinas A et al. Predicting Mortality Due to SARS-CoV-2: A  
402 Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico.  
403 *The Journal of Clinical Endocrinology & Metabolism*. 2020;105(8):2752-2761.
- 404 6. Docherty A, Harrison E, Green C, Hardwick H, Pius R, Norman L et al. Features of  
405 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical  
406 Characterisation Protocol: prospective observational cohort study. *BMJ*. 2020;369:  
407 m1985.
- 408 7. Javanmardi F, Keshavarzi A, Akbari A, Emami A, Pirbonyeh N. Prevalence of  
409 underlying diseases in died cases of COVID-19: A systematic review and meta-  
410 analysis. *PLOS ONE*. 2020;15(10):e0241265.
- 411 8. Moons K, Altman D, Reitsma J, Ioannidis J, Macaskill P, Steyerberg E et al.  
412 Transparent Reporting of a multivariable prediction model for Individual Prognosis Or  
413 Diagnosis (TRIPOD): Explanation and Elaboration. *Annals of Internal Medicine*.  
414 2015;162(1):W1-73.

- 415 9. Julius General Practitioner's Network (JGPN).  
416 <https://juliuscentrum.umcutrecht.nl/nl/julius-huisartsen-netwerk>. Accessed 07 May  
417 2021.
- 418 10. Academisch Huisartsennetwerk AMC (AHA). [https://huisartsgeneeskunde-](https://huisartsgeneeskunde-amc.maglr.com/amsterdam_umc_huisartsgeneeskunde_amc_jaarbeeld_2018/academisch-huisartsennetwerk-amc)  
419 [amc.maglr.com/amsterdam\\_umc\\_huisartsgeneeskunde\\_amc\\_jaarbeeld\\_2018/academisch-huisartsennetwerk-amc](https://huisartsgeneeskunde-amc.maglr.com/amsterdam_umc_huisartsgeneeskunde_amc_jaarbeeld_2018/academisch-huisartsennetwerk-amc). Accessed 07 May 2021.
- 420  
421 11. Academisch Netwerk Huisartsgeneeskunde VU (ANH).  
422 <https://www.vumc.nl/anh/database-anh.htm>. Accessed 07 May 2021.
- 423 12. Riley RD, Ensor J, Snell KIE, Harrell FE, Martin GP, Reitsma JB, et al. Calculating the  
424 sample size required for developing a clinical prediction model. *BMJ*. 2020;368:1–12.
- 425 13. Harrell Jr FE. Regression modeling strategies: with applications to linear models,  
426 logistic and ordinal regression, and survival analysis. [Internet]. 2<sup>nd</sup> edition. Springer.  
427 2015. Accessed 11 May 2021. Available via:  
428 <https://link.springer.com/content/pdf/10.1007/978-3-319-19425-7.pdf>.
- 429 14. R Core Team. R: A language and environment for statistical computing. R Foundation  
430 for Statistical Computing, Vienna, Austria. 2020. Available via: [https://www.R-](https://www.R-project.org/)  
431 [project.org/](https://www.R-project.org/).
- 432 15. Harrell Jr FE. rms: Regression Modeling Strategies. R package version 6.2-0. 2021.  
433 Available via: <https://CRAN.R-project.org/package=rms>.
- 434 16. Xavier R, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an  
435 open-source package for R and S+ to analyze and compare ROC curves. *MC*  
436 *Bioinforma*. 2011;12:77.
- 437 17. Andri Signorell et mult. al. DescTools: Tools for descriptive statistics. R package  
438 version 0.99.41. 2021.
- 439 18. Brown M. rmda: Risk Model Decision Analysis. R package version 1.6. 2018, Available  
440 via: <https://CRAN.R-project.org/package=rmda>.
- 441 19. Little P, Stuart B, Smith S, Thompson MJ, Knox K, Van Den Bruel A, et al. Antibiotic  
442 prescription strategies and adverse outcome for uncomplicated lower respiratory tract



- 443 infections: Prospective cough complication cohort (3C) study. *BMJ*. 2017;357.
- 444 20. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A  
445 comparison with young and middle-aged patients. *Journal of Infection*.  
446 2020;80(6):e14-e18.
- 447 21. Liu W, Tao Z, Wang L, Yuan M, Liu K, Zhou L et al. Analysis of factors associated with  
448 disease outcomes in hospitalized patients with 2019 novel coronavirus disease.  
449 *Chinese Medical Journal*. 2020;133(9):1032-1038.
- 450 22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients  
451 infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497–  
452 506.
- 453 23. Haitao T, Vermunt J, Abeykoon J, Ghamrawi R, Gunaratne M, Jayachandran M et al.  
454 COVID-19 and Sex Differences. *Mayo Clinic Proceedings*. 2020;95(10):2189-2203.
- 455 24. Gebhard C, Regitz-Zagrosek V, Neuhauser H, Morgan R, Klein S. Impact of sex and  
456 gender on COVID-19 outcomes in Europe. *Biology of Sex Differences*. 2020;11(1).
- 457 25. Nishiga M, Wang D, Han Y, Lewis D, Wu J. COVID-19 and cardiovascular disease:  
458 from basic mechanisms to clinical perspectives. *Nature Reviews Cardiology*.  
459 2020;17(9):543-558.
- 460 26. Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk stratification of  
461 patients admitted to hospital with covid-19 using the ISARIC WHO Clinical  
462 Characterisation Protocol: Development and validation of the 4C Mortality Score. *BMJ*.  
463 2020;370: m3339.
- 464 27. Clift AK, Coupland CAC, Keogh RH, Diaz-Ordaz K, Williamson E, Harrison EM, et al.  
465 Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality  
466 from coronavirus 19 in adults: national derivation and validation cohort study. *BMJ*.  
467 2020;371 :m3731.
- 468 28. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors  
469 associated with COVID-19-related death using OpenSAFELY. *Nature*.  
470 2020;584(7821):430–436.

- 471 29. Ramakrishnan S, Nicolau DV, Langford B, Mahdi M, Jeffers H, Mwasuku C, et al.  
472 Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-  
473 label, randomised controlled trial. *Lancet Respir Med.* 2021;19(21):1–10.
- 474 30. Tardif J, Bouabdallaoui N, Allier PLL, Gaudet D, Shah B, Pillinger MH, et al. Efficacy of  
475 Colchicine in Non-Hospitalized Patients with COVID-19. *MedRxiv.*  
476 021.01.26.21250494

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495 **Tables and figures**

496 **Table 1** - Baseline characteristics of the development cohort of 5,475 community patients  
 497 with confirmed or clinically suspected COVID-19 from the 'first wave' in the Netherlands

498

| <b>Characteristics</b>                 | <b>JGPN<br/>(n=2,825)</b> | <b>ANH<br/>(n=2,650)</b> |
|--|---------------------------|--------------------------|
| Age in years (IQR)                     | 48 (34-62)                | 49 (36-62)               |
| Male sex                               | 1144 (40.1%)              | 1068 (40.3%)             |
| <b>Cardiovascular diseases</b>         |                           |                          |
| Heart failure                          | 109 (3.9%)                | 80 (3.0%)                |
| Coronary artery disease                | 230 (8.1%)                | 189 (7.1%)               |
| Atrial fibrillation                    | 139 (4.9%)                | 177 (6.7%)               |
| Peripheral arterial disease            | 49 (1.7%)                 | 37 (1.4%)                |
| History of stroke/TIA                  | 136 (4.8%)                | 117 (4.4%)               |
| History of VTE                         | 123 (4.4%)                | 100 (3.8%)               |
| Type 2 diabetes mellitus               | 300 (10.6%)               | 262 (9.9%)               |
| CVD 0                                  | 2132 (75.5%)              | 2053 (77.5%)             |
| CVD 1                                  | 440 (15.6%)               | 386 (14.6%)              |
| CVD ≥2                                 | 253 (9.0%)                | 211 (8.0%)               |
| <b>Other comorbidities</b>             |                           |                          |
| History of any cancer                  | 198 (7.0%)                | 207 (7.8%)               |
| Hypertension                           | 721 (25.5%)               | 616 (23.2%)              |
| Hypercholesterolemia                   | 261 (9.2%)                | 331 (12.5%)              |
| All pulmonary disease                  | 575 (20.4%)               | 432 (16.3%)              |
| COPD                                   | 234 (8.3%)                | 155 (5.8%)               |
| Asthma                                 | 434 (15.4%)               | 315 (11.9%)              |
| BMI in kg/m <sup>2</sup> (IQR)         | 27 ( 24-31) (n=1,091)     | 27 ( 24-31)<br>(n=1,072) |
| Median oxygen saturation in %<br>(IQR) | 98 (95-98) (n=191)        | 98 (96-99 ) (n=87)       |
| CRP in mg/L (IQR)                      | 6 (2-23) (n=480)          | 3 (1-9) (n=646)          |
| Hospital referrals                     | 185 (6.5%)                | 188 (7.1%)               |

499

500 Patient characteristics of 5,475 primary care (clinically suspected) COVID-19 patients.

501 BMI = Body Mass Index; CRP = C-reactive protein; CVD = cardiovascular disease; IQR =  
 502 interquartile range; TIA = transient ischemic attack; VTE=venous thromboembolism.

503

504 **Table 2** - Baseline characteristics of the validation cohort of 16,693 community patients with  
 505 confirmed COVID-19

506

| <b>Characteristics</b>              | <b>JGPN<br/>(n=5,420)</b> | <b>ANH<br/>(n=4,989)</b> | <b>AHA<br/>(n=6,284)</b> |
|-------------------------------------|---------------------------|--------------------------|--------------------------|
| Age in years (IQR)                  | 43 (30-56)                | 47 (34-59)               | 49 (36-60)               |
| Male sex                            | 2400 (44.3%)              | 2121 (42.5%)             | 2462 (39.2%)             |
| <b>Cardiovascular diseases</b>      |                           |                          |                          |
| Heart failure                       | 86 (1.6%)                 | 64 (1.3%)                | 101 (1.6%)               |
| Coronary artery disease             | 262 (4.8%)                | 270 (5.4%)               | 346 (5.5%)               |
| Atrial fibrillation                 | 122 (2.3%)                | 139 (2.8%)               | 176 (2.8%)               |
| Peripheral arterial disease         | 39 (0.7%)                 | 44 (0.9%)                | 39 (0.6%)                |
| History of stroke/TIA               | 123 (2.3%)                | 151 (3.0%)               | 229 (3.6%)               |
| History of VTE                      | 124 (2.3%)                | 134 (2.7%)               | 226 (3.6%)               |
| Type 2 diabetes mellitus            | 476 (8.8%)                | 495 (9.9%)               | 715 (11.4%)              |
| CVD 0                               | 4566 (84.2%)              | 4059 (81.4%)             | 4964 (79.0%)             |
| CVD 1                               | 586 (10.8%)               | 663 (13.3%)              | 955 (15.2%)              |
| CVD ≥2                              | 268 (4.9%)                | 267 (5.4%)               | 365 (4.8%)               |
| <b>Other comorbidities</b>          |                           |                          |                          |
| History of any cancer               | 207 (3.8%)                | 331 (6.6%)               | 304 (4.8%)               |
| Hypertension                        | 883 (16.3%)               | 1,009 (20.2%)            | 1,486 (23.6%)            |
| Hypercholesterolemia                | 309 (5.7%)                | 493 (9.9%)               | 527 (8.4%)               |
| <b>All pulmonary diseases</b>       | 648 (12.0%)               | 610 (12.2%)              | 867 (13.8%)              |
| COPD                                | 174 (3.2%)                | 186 (3.7%)               | 184 (2.9%)               |
| Asthma                              | 534 (9.9%)                | 477 (9.0%)               | 726 (11.6%)              |
| BMI in kg/m <sup>2</sup> (IQR)      | 28 (24-32) (n=1,685)      | 27 (24-32) (n=1,823)     | 29 (25-33) (n=2,178)     |
| Median oxygen saturation in % (IQR) | 98 (96-98) (n=176)        | 98 (97-99) (n=134)       | 98 (97-99) (n=75)        |
| CRP in mg/L (IQR)                   | 3 (2-12) (n=545)          | 2 (1-5) (n=936)          | 3 (1-10) (n=1,055)       |
| Hospital referrals                  | 219 (4.0%)                | 187 (3.7%)               | 357 (5.7%)               |

507

508 Patients characteristics of 16,693 primary care COVID-19 patients.

509 BMI = Body Mass Index; CRP = C-reactive protein; CVD = cardiovascular disease; IQR =

510 interquartile range; TIA = transient ischemic attack; VTE=venous thromboembolism.

511

512

513 **Table 3** - Model development and internal validation using logistic regression

514

| Predictor                                | Full model             |                         | Simple model           |                         |
|--|------------------------|-------------------------|------------------------|-------------------------|
|  | Regression coefficient | 95% confidence interval | Regression coefficient | 95% confidence interval |
| Intercept                                | -4.110                 | -6.338; -2.149          | -3.988                 | -6.228; -2.038          |
| Age                                      | 0.026                  | -0.034; 0.092           | 0.022                  | -0.037; 0.088           |
| Age'                                     | 0.045                  | -0.170; 0.251           | 0.085                  | -0.127; 0.289           |
| Age''                                    | -0.172                 | -0.719; 0.389           | -0.268                 | -0.809; 0.286           |
| Female sex                               | 0.324                  | -2.358; 3.105           | 0.214                  | -2.450; 2.974           |
| Interaction sex and age                  | -0.019                 | -0.102; 0.062           | -0.016                 | -0.099; 0.065           |
| Interaction sex and age'                 | 0.032                  | -0.247; 0.314           | 0.015                  | -0.262; 0.296           |
| Interaction sex and age''                | -0.056                 | -0.805; 0.686           | -0.014                 | -0.758; 0.726           |
| CVD 1                                    | 0.564                  | 0.280; 0.844            |                        |                         |
| CVD ≥2                                   | 0.636                  | 0.282; 0.983            |                        |                         |
| <i>Apparent c-statistic</i>              | 0.693                  | 0.665; 0.721            | 0.681                  | 0.653; 0.710            |
| <i>R<sup>2</sup>cs</i>                   | 0.030                  | 0.021; 0.039            | 0.026                  | 0.018; 0.035            |
| <i>Internal validation c-statistic</i>   | 0.688                  | 0.660; 0.716            | 0.680                  | 0.652; 0.708            |
| <i>Internal validation R<sup>2</sup></i> | 0.070                  |                         | 0.061                  |                         |
| <i>Internal validation slope</i>         | 0.965                  |                         | 0.957                  |                         |

515

516 Regression coefficients with 95% confidence intervals, c-statistic, and internal validation  
 517 performance measures of the full model with predictors age, sex and number of  
 518 cardiovascular diseases and the simple model with only age, sex and the interaction  
 519 between age and sex as predictors. Age was divided into three subgroups (shown as age,  
 520 age' and age'') using restricted cubic spline function to account for non-linearity. CVD =  
 521 cardiovascular disease; R<sup>2</sup>cs = R<sup>2</sup> Cox-Snell.

522

523

524 **Table 4** – Comparing the full and the simple model

525

|  |                               |
|--|-------------------------------|
| <b><math>\Delta</math>AUC</b>                | 0.012                         |
| <b><math>\Delta</math>R<sup>2</sup>cs</b>    | 0.004                         |
| <b>Likelihood ratio, <math>\chi^2</math></b> | 19.531, df=2, $p = 5.740e-05$ |

526

527  $\Delta$ AUC,  $\Delta$ R<sup>2</sup>cs and Deviance in comparing model with and model without number of  
528 cardiovascular diseases (0, 1 or  $\geq 2$ ) modelled.  $\Delta$ AUC is calculated by subtracting model 2  
529 unadjusted c-statistic from model 1 unadjusted c-statistic.  $\Delta$ R<sup>2</sup>cs is calculated by subtracting  
530 model 2 R<sup>2</sup>cs from model 1 R<sup>2</sup>cs.

531

532 **Table 5** - performance temporal validation

533

|  | <b>Total validation population (n=16,693)</b> | <b>Total patients JGPN (n=5,420)</b> | <b>Total patients AHA (n=6,284)</b> | <b>Total patients ANH (n=4,989)</b> |
|--|---|--------------------------------------|-------------------------------------|-------------------------------------|
| Area under the curve   | 0.747 (CI 0.729; 0.764)                       | 0.780 (CI 0.750; 0.810)              | 0.718 (CI 0.691; 0.745)             | 0.751 (CI 0.714; 0.789)             |
| Calibration slope  | 1.358 (CI 1.246; 1.471)                       | 1.510 (CI 1.306; 1.718)              | 1.218 (CI 1.050; 1.387)             | 1.415 (1.190; 1.645)                |
| Calibration intercept  | -0.333 (CI -0.408; -0.261)                    | -0.396 (CI -0.535; -0.262)           | -0.143 (CI -0.253; -0.036)          | -0.561 (CI -0.712; -0.416)          |
| Calibration in the large:<br>Mean observed risk<br>Mean predicted risk | 0.046<br>0.062                                | 0.040<br>0.058                       | 0.057<br>0.065                      | 0.038<br>0.063                      |
| R <sup>2</sup> cs  | 0.035 (CI 0.029; 0.041)                       | 0.040 (CI 0.030; 0.050)              | 0.033 (CI 0.024; 0.042)             | 0.032 (CI 0.021; 0.042)             |
| Brier score  | 0.042 (CI 0.039; 0.045)                       | 0.037 (CI 0.033; 0.041)              | 0.052 (CI 0.047; 0.056)             | 0.035 (CI 0.031; 0.040)             |

534


535 Temporal validation performance measures with 95% confidence intervals (CI). R<sup>2</sup>cs = R<sup>2</sup>

536 Cox-Snell.

537

538 **Figure 1** – Predicted risk of hospitalisation

539




540

541 Plotted risk of escalation of care resulting in hospital referral in (clinically suspected) COVID-  
542 19 primary care patients at a certain age and stratified by sex and by the number of  
543 underlying cardiovascular diseases and/or diabetes (i.e. 0, 1, or  $\geq 2$ ). Confidence intervals are  
544 shown in grey.

545



546 **Figure 2** – Calibration plot



547

548

549 Calibration plot in the total validation cohort with hospitalisation as the outcome